PURPOSE: Mechanistic and observational studies support an independent increase in risk of hypertension and abnormal glucose metabolism associated with obstructive sleep apnea (OSA). However, the specific populations and outcomes that improve with treatment of OSA in clinical practice are not established. We examined the effectiveness of OSA treatment on clinical blood pressure and diabetes control measures in men with preexisting systemic hypertension or type 2 diabetes. METHODS: A retrospective cohort of veterans (n = 221) with a new diagnosis of OSA and initiation of positive airway pressure treatment was identified using administrative databases and clinical records. MEASUREMENTS AND RESULTS: Outcomes were changes in blood pressure (BP; mean of 3 highest recordings; systolic and diastolic) and glycemic control (mean of 3 highest fasting glucose and hemoglobinA1C values) at 3-6 months (T1) and 9-12 months (T2) following treatment compared to pretreatment. A generalized estimating equation model was used with adjustment for potential confounders: demographics, body mass index (BMI), OSA severity, Charlson comorbidity index, and pharmacologic treatment for hypertension and diabetes. Sustained independent effects of OSA treatment (mean change [95% CI]) were noted in both systolic BP (T1; -7.44 [-10.41 to -4.47] and T2; -6.81 [-9.94 to -3.67]) and diastolic BP (T1; -3.14, [-4.99 to -1.29] and T2; -3.69, [-5.53 to -1.85]). Diabetes control measures did not change with OSA treatment. CONCLUSIONS: Treatment of OSA improves office blood pressure in hypertensive men. Prospective studies are necessary to better characterize specific populations with OSA that benefit from treatment with respect to progression of hypertension and type 2 diabetes.
PURPOSE: Mechanistic and observational studies support an independent increase in risk of hypertension and abnormal glucose metabolism associated with obstructive sleep apnea (OSA). However, the specific populations and outcomes that improve with treatment of OSA in clinical practice are not established. We examined the effectiveness of OSA treatment on clinical blood pressure and diabetes control measures in men with preexisting systemic hypertension or type 2 diabetes. METHODS: A retrospective cohort of veterans (n = 221) with a new diagnosis of OSA and initiation of positive airway pressure treatment was identified using administrative databases and clinical records. MEASUREMENTS AND RESULTS: Outcomes were changes in blood pressure (BP; mean of 3 highest recordings; systolic and diastolic) and glycemic control (mean of 3 highest fasting glucose and hemoglobinA1C values) at 3-6 months (T1) and 9-12 months (T2) following treatment compared to pretreatment. A generalized estimating equation model was used with adjustment for potential confounders: demographics, body mass index (BMI), OSA severity, Charlson comorbidity index, and pharmacologic treatment for hypertension and diabetes. Sustained independent effects of OSA treatment (mean change [95% CI]) were noted in both systolic BP (T1; -7.44 [-10.41 to -4.47] and T2; -6.81 [-9.94 to -3.67]) and diastolic BP (T1; -3.14, [-4.99 to -1.29] and T2; -3.69, [-5.53 to -1.85]). Diabetes control measures did not change with OSA treatment. CONCLUSIONS: Treatment of OSA improves office blood pressure in hypertensivemen. Prospective studies are necessary to better characterize specific populations with OSA that benefit from treatment with respect to progression of hypertension and type 2 diabetes.
Authors: John M Flack; Domenic A Sica; George Bakris; Angela L Brown; Keith C Ferdinand; Richard H Grimm; W Dallas Hall; Wendell E Jones; David S Kountz; Janice P Lea; Samar Nasser; Shawna D Nesbitt; Elijah Saunders; Margaret Scisney-Matlock; Kenneth A Jamerson Journal: Hypertension Date: 2010-10-04 Impact factor: 10.190
Authors: A G Logan; S M Perlikowski; A Mente; A Tisler; R Tkacova; M Niroumand; R S Leung; T D Bradley Journal: J Hypertens Date: 2001-12 Impact factor: 4.844
Authors: Clete A Kushida; Richard B Berry; Alexander Blau; Tami Crabtree; Ingo Fietze; Meir H Kryger; Samuel T Kuna; G Vernon Pegram; Thomas Penzel Journal: Sleep Date: 2011-08-01 Impact factor: 5.849
Authors: Jan Börgel; Bernd Martin Sanner; Fatih Keskin; Andrea Bittlinsky; Nina Karen Bartels; Nikolaus Büchner; Anika Huesing; Lars Christian Rump; Andreas Mügge Journal: Am J Hypertens Date: 2004-12 Impact factor: 2.689
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: M Alajmi; A T Mulgrew; J Fox; W Davidson; M Schulzer; E Mak; C F Ryan; J Fleetham; P Choi; N T Ayas Journal: Lung Date: 2007-03-28 Impact factor: 2.584
Authors: Jamie Chung Mei Lam; Agnes Yuen Kwan Lai; Terence Chi Chun Tam; Michele Mae Ann Yuen; Karen Siu Ling Lam; Mary Sau Man Ip Journal: Sleep Breath Date: 2016-11-05 Impact factor: 2.816
Authors: Ikuyo Imayama; Ahana Gupta; Pei-Shan Yen; Yi-Fan Chen; Brendan Keenan; Raymond R Townsend; Julio A Chirinos; Frances M Weaver; David W Carley; Samuel T Kuna; Bharati Prasad Journal: J Clin Sleep Med Date: 2022-05-01 Impact factor: 4.324
Authors: Urmi Sheth; Rebecca S Monson; Bharati Prasad; Ashima S Sahni; Sara Matani; Tomas Mercado; Maureen A Smith; Melissa A Carlucci; Kirstie K Danielson; Sirimon Reutrakul Journal: J Clin Sleep Med Date: 2021-08-01 Impact factor: 4.324
Authors: J Daryl Thornton; Katherine A Dudley; Gul Jana Saeed; Sheeja T Schuster; Amy Schell; James C Spilsbury; Sanjay R Patel Journal: Ann Am Thorac Soc Date: 2022-02